Assessing Dentsply Sirona (XRAY) Valuation After Steep Share Price And Earnings Setbacks
Dentsply Sirona (XRAY) has experienced significant share price and earnings setbacks, with its stock down 35.47% over the past year. Despite this, Simply Wall St's analysis suggests the company is 78.4% undervalued, with a fair value of $45.50 against a current price of $9.84, based on its position as a dental equipment provider. The valuation hinges on the durability of dental demand and profit margins, but the company faces challenges from soft equipment cycles and recent losses.
Registration opens for reimagined DS World Las Vegas
Registration is now open for Dentsply Sirona World Las Vegas 2026, scheduled for September 24–26 at the MGM Grand Conference Center. This biennially held event has been redesigned to focus more on practical, hands-on learning, offering over 60 training opportunities and 35 lectures for dental professionals across various roles. Attendees can earn up to 15 continuing education credits and explore innovations shaping connected dentistry.
Dentsply Sirona stock (US9839191015): Conference spotlight after Q1 update
Dentsply Sirona (XRAY) will present at the 2026 Stifel Jaws & Paws Conference on May 27, following its Q1 2026 results which showed net sales of approximately $945 million. The company, a Nasdaq-listed dental equipment supplier, focuses on imaging systems, CAD/CAM tools, and recurring consumables. This conference appearance offers investors an opportunity to hear management's insights on execution, product launches, and market trends, beyond the recent quarterly report.
Dentsply Sirona Inc stock (US24906P1093): dental specialist reacts to latest quarterly results
Dentsply Sirona Inc.'s recent Q1 2026 results show modest organic growth, driven by digital dentistry and specialty products, with adjusted EPS slightly above guidance. The company, a key player in dental technology, reaffirmed its full-year 2026 guidance and 2025 targets, indicating confidence despite macroeconomic uncertainties. The stock's muted reaction reflects investors weighing earnings upside against a cautious demand environment.
Dentsply Sirona to Participate in the 2026 Stifel Jaws & Paws Conference
Dentsply Sirona announced its participation in the 2026 Stifel Jaws & Paws Conference, with management scheduled to present on May 27, 2026, at 3:35 p.m. ET. A live audio webcast and replay will be available on the company's investor relations website. Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies.
Dentsply Sirona to Participate in the 2026 Stifel Jaws & Paws Conference
Dentsply Sirona announced its participation in the 2026 Stifel Jaws & Paws Conference. The company's management is scheduled to present on Wednesday, May 27, 2026, at 3:35 p.m. ET. A live audio webcast and replay will be available on the Investors section of the Dentsply Sirona website.
Dentsply Sirona Inc stock (US9839191015): dividend strength and macro pressure move into focus
Dentsply Sirona Inc (XRAY) is highlighted for its sustained dividend growth and attractive yield, appealing to income-focused investors despite recent share price pressure from higher US wholesale inflation. The company's business model, which balances steady consumable revenue with cyclical equipment sales, is adapting to digitalization in dentistry. However, challenges such as negative trailing net margins, restructuring impacts, and macroeconomic headwinds necessitate close monitoring of its financial performance and strategic execution.
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
Several healthcare stocks, including Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics, experienced declines after the April PPI report indicated accelerating wholesale inflation. The report highlighted increased operating costs for healthcare providers due to rising service-sector inflation and potential regulatory intervention targeting drug pricing. Despite the broader market reaction, the article suggests that significant price drops could present buying opportunities for high-quality stocks.
Dentsply Sirona stock (US24906P1093): dental specialist updates 2026 guidance after solid quarter
Dentsply Sirona has updated its 2026 financial targets following a strong start to the year and advancements in its efficiency program, based on its Q1 2024 results and subsequent investor communications. The company reported net sales of roughly $953 million and adjusted EPS of $0.42 for Q1 2024, maintaining its full-year 2024 guidance and linking 2026 goals to continued restructuring and investments in digital workflows. Key revenue drivers include imaging and CAD/CAM systems, consumables, implants, and clear aligners, with an emphasis on integrated solutions and disciplined capital allocation.
ETF investissant dans des actions DENTSPLY SIRONA, Inc.
This article lists various ETFs that hold shares of DENTSPLY SIRONA, Inc. (XRAY), categorized by market value. It provides details such as market value, weight, issuer, management style, expense ratio, AUM, price, change, volume, and 3-year total NAV return for each ETF. The information aims to help investors identify funds containing DENTSPLY SIRONA stock, facilitating investment with potentially lower risk.
Dentsply Sirona stock (US9839191015): Q1 earnings miss and updated FY guidance
Dentsply Sirona (XRAY) reported its Q1 2026 earnings, with adjusted EPS of $0.27, missing estimates by $0.01, though revenue of $880 million surpassed expectations. The company updated its full-year 2026 guidance for EPS to $1.40-$1.50 and revenue to $3.5-$3.6 billion. The article highlights Dentsply Sirona's position as a global leader in dental products and technologies, emphasizing recurring revenue from consumables, equipment sales, and the company's focus on innovation in a growing digital dentistry market.
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
Shares of Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics fell in the afternoon trading session following the release of the April PPI report, which indicated an acceleration in wholesale inflation to 6% annually. The report highlighted a significant rise in service-sector prices, creating headwinds for healthcare companies due to increased operating costs and potential regulatory intervention concerning drug pricing. Amidst this market reaction, Collegium Pharmaceutical's stock showed particular volatility but had previously seen a substantial gain six months prior due to strong Q3 2025 financial results.
Dentsply Sirona launches AI-enabled diagnostic aid for periapical radiolucencies
Dentsply Sirona has introduced Smart View – Detect, an AI-powered diagnostic tool for identifying periapical radiolucencies in CBCT scans. This software is the first of its kind to receive US FDA clearance and CE marking for the EU market, aiming to improve diagnostic efficiency and clarity for clinicians. Available through DS Core, it enhances patient communication and integrates with existing Dentsply Sirona CBCT systems.
UBS Group AG Grows Holdings in DENTSPLY SIRONA Inc. $XRAY
UBS Group AG significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 63.7% in the fourth quarter, now holding 1.7 million shares valued at approximately $19.5 million. This increase occurred despite the company missing quarterly earnings estimates by a penny, though revenue exceeded expectations. Analyst sentiment remains cautious with a "Hold" consensus rating and an average price target of $13.82.
DENTSPLY SIRONA Inc. $XRAY Shares Acquired by First Eagle Investment Management LLC
First Eagle Investment Management LLC increased its stake in DENTSPLY SIRONA Inc. by 3.2% in the fourth quarter, bringing its total holdings to 14.64 million shares valued at approximately $167.3 million. This increase comes as other institutional investors have also adjusted their positions in the medical instruments supplier. DENTSPLY SIRONA recently reported Q1 earnings with EPS slightly below estimates but revenue exceeding expectations, and has provided guidance for FY 2026 EPS.
Is Dentsply Sirona (XRAY) Now Offering Value After A 28% One Year Share Price Slide
Dentsply Sirona (XRAY) has experienced significant share price declines over the past year, three years, and five years, leading Simply Wall St to assess its current valuation. Using Discounted Cash Flow (DCF) and Price-to-Sales (P/S) ratio analyses, the stock appears significantly undervalued, with a DCF model suggesting a 64.9% discount and its P/S ratio being well below industry averages. The article also presents contrasting narratives for Dentsply Sirona's future, ranging from a "durability story" justifying a higher fair value to a more cautious view emphasizing competition and cost pressures.
Vanguard Group Inc. Has $249.87 Million Stock Position in DENTSPLY SIRONA Inc. $XRAY
Vanguard Group Inc. reduced its stake in DENTSPLY SIRONA Inc. by 0.7% in the fourth quarter, yet still holds 21.86 million shares valued at $249.87 million, representing about 10.96% of the company. Several insiders, including directors James D. Forbes and Gregory T. Lucier, recently acquired shares, totaling 70,000 shares worth approximately $956,437. Analysts are largely neutral to cautious on the stock, with a consensus "Hold" rating and an average price target of $13.82, while the company reported mixed quarterly results, missing EPS but beating revenue estimates.
DENTSPLY SIRONA Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:XRAY) 2026-05-08
DENTSPLY SIRONA Inc. (XRAY) has released its Q1 2026 earnings call presentation. The company reported an EPS of $0.27, missing estimates by $0.00, while revenue of $880.00M beat expectations by $39.92M, representing a 0.11% year-over-year increase. This presentation accompanies their earnings call discussing these results.
DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $14.00 by Analysts at Mizuho
Mizuho has lowered its price target for DENTSPLY SIRONA (NASDAQ:XRAY) to $14, down from $16, while maintaining a "neutral" rating. This adjustment comes after the company's Q1 revenue of $880 million beat estimates, but adjusted EPS of $0.27 missed by $0.01 and the company reported a GAAP loss. The firm's FY 2026 EPS guidance of $1.40–$1.50 is broadly in line, but the company faces ongoing margin pressures from U.S. market softness, tariffs, and transformation costs.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Q1 2026 Earnings Call Transcript
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) reported its Q1 2026 earnings, missing EPS expectations with $0.27 against an anticipated $0.28. The company is actively implementing a "return to growth" action plan focused on strengthening execution, investing in key growth areas, and optimizing cost structure, which is showing early traction despite ongoing external pressures. Management reaffirmed its full-year 2026 outlook for net sales between $3.5 billion and $3.6 billion and adjusted EPS in the range of $1.40 to $1.50, anticipating more significant improvements in the second half of the year and into 2027-2028.
DENTSPLY SIRONA Inc. 1Q 2026: Revenue $880M, EPS ($0.05) — 10-Q Summary
DENTSPLY SIRONA Inc. reported its first-quarter 2026 results, showing flat revenue year-over-year at $880 million but a net loss of ($10M) and diluted EPS of ($0.05), a significant decrease from the prior year's net income. The company attributed revenue stagnation to lower volumes in EDS and OIS, and reduced distributor inventory, while also initiating a restructuring plan aimed at $120M in annualized savings. R&D spending is being increased to expand digital workflows and DS Core.
Dentsply Sirona stock held at Hold by Needham on execution risk
Needham has maintained its "Hold" rating on Dentsply Sirona (NASDAQ:XRAY) due to execution risk, despite the company's first-quarter 2026 revenue exceeding consensus estimates. Although Q1 earnings per share missed expectations by one cent, the company reiterated its guidance and is implementing a "Return to Growth" action plan. Needham expressed concern that the path to growth may not be linear, leading to the continued "Hold" rating.
Dentsply Needs to Execute on Return-to-Growth and Restructuring Plan to Regain Investor Confidence
Dentsply Sirona, a major dental equipment manufacturer, is facing increased competition and investor pressure. The company is strategically adapting by opening up its previously closed Cerec workflow to integrate with third-party equipment and expanding partnerships, aiming to broaden its market reach and regain investor confidence through its return-to-growth and restructuring plan. Soft Q1 earnings have further heightened the urgency for successful execution of its turnaround timeline.
Dentsply Sirona Q1 2026 Earnings Call Transcript
Dentsply Sirona announced its Q1 2026 financial results, with management emphasizing a focus on sustainable growth, strong leadership, and new competitive hires. Key strategic priorities include returning the US to growth, enhancing the implant business, and increasing R&D investment in high-value opportunities. The company detailed recent product launches and expanded distribution networks, while also outlining restructuring efforts to achieve $120 million in annual savings and a capital allocation strategy prioritizing debt reduction and share repurchases.
[10-Q] DENTSPLY SIRONA Inc. Quarterly Earnings Report
DENTSPLY SIRONA Inc. (XRAY) reported its Q1 2026 earnings, showing a net loss of $10 million compared to a net income of $19 million in Q1 2025. The company's net sales remained flat year-over-year at $880 million, with a decrease in gross profit margin. The report highlights increased R&D expenses, significant restructuring costs, and ongoing litigation challenges, reflecting a period of strategic adjustments and operational focus amid global economic uncertainties.
Profit falls as Dentsply Sirona (Nasdaq: XRAY) keeps 2026 outlook
Dentsply Sirona reported flat sales of $880 million in Q1 2026 but saw a significant drop in profitability, with a GAAP net loss of $10 million and adjusted EPS falling 39% to $0.27. Despite the weaker earnings, the company reaffirmed its full-year 2026 outlook for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50, citing progress on its transformation plan and improved operating cash flow. Strategic initiatives included the launch of an AI-enabled diagnostic aid and new distribution agreements.
DENTSPLY SIRONA (NASDAQ:XRAY) Announces Quarterly Earnings Results
DENTSPLY SIRONA (NASDAQ:XRAY) reported its quarterly earnings, with an EPS of $0.27, missing consensus estimates by $0.01, but revenue of $880.0 million exceeded expectations. The company updated its FY 2026 EPS guidance to $1.40–$1.50, and its stock rose about 1.5% on increased trading volume. Insider buying by directors and significant institutional investment, particularly from Goldman Sachs, were noted.
Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Reports Q1 Revenue $880.0M, vs. FactSet Est of $841.8M
DENTSPLY SIRONA Inc. (XRAY) reported its Q1 revenue reached $880.0 million, surpassing the FactSet estimate of $841.8 million. The company also announced Q1 adjusted EPS of $0.27 per share, slightly below the FactSet estimate of $0.28 per share. This financial news was accompanied by details of their Q1 2026 earnings call and recent product innovations.
Dentsply Sirona Reports First Quarter 2026 Results
Dentsply Sirona reported its Q1 2026 financial results, with net sales of $880 million and an adjusted EPS of $0.27, reiterating its full-year 2026 outlook. The company is actively executing its Return-to-Growth Action Plan, including the launch of AI-enabled diagnostic aids and expansion of distribution agreements, despite facing near-term external pressures.
Assessing Dentsply Sirona (XRAY) Valuation As Quarterly Results And Institutional Interest Converge
Dentsply Sirona (XRAY) is approaching its quarterly earnings report with an anticipated decline in year-over-year revenue, despite recent institutional interest from Ariel Investments and Vanguard. The stock is currently trading at US$11.81, significantly below an analyst-estimated fair value of $45.50, suggesting a potential undervaluation. The company, a major dental equipment and consumables provider, faces the challenge of turning a substantial loss into sustainable profitability while maintaining revenue growth in a tightening market.
Dentsply Sirona launches updated SureSmile software
Dentsply Sirona has released an updated version of its SureSmile software, designed to enhance the user experience for dental professionals. The improvements include a more comprehensive patient overview, streamlined tasks, and better digital lab communication. Users can now also upload patient photos directly from mobile devices and refine orders without needing new images.
Dentsply Sirona expands distribution deal with Atlanta Dental By Investing.com
Dentsply Sirona announced an expanded distribution agreement with Atlanta Dental Supply, effective August 1, to distribute its digital dentistry technologies, including the CEREC system in the U.S. This partnership aims to broaden Dentsply Sirona's reach by leveraging Atlanta Dental Supply's established customer relationships in the Southeast. Despite positive revenue results for Q4 2025, Dentsply Sirona's EPS fell short, leading Mizuho to adjust its price target and lower EPS estimates for 2026 and 2027.
Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply
Dentsply Sirona has announced an expanded distribution agreement with Atlanta Dental Supply, effective August 1st, to broaden its reach in the U.S. market. Through this partnership, Atlanta Dental Supply will offer Dentsply Sirona's connected technology solutions, including CEREC systems, intraoral scanning, and digital imaging solutions, strengthening Dentsply Sirona's digital dentistry offerings in the Southeast. This move aims to leverage Atlanta Dental Supply's regional presence and customer relationships to enhance commercial execution and expand access to Dentsply Sirona's innovative products.
CEREC and dental scanners reach more U.S. practices on Aug. 1
Dentsply Sirona (Nasdaq: XRAY) has announced an enhanced distribution agreement with Atlanta Dental Supply, effective August 1, 2026. This partnership will expand access to Dentsply Sirona's digital dentistry portfolio, including CEREC systems and intraoral scanners, to practices across the U.S. Southeast. The collaboration leverages Atlanta Dental Supply's established regional presence and customer relationships to strengthen Dentsply Sirona's market strategy.
DENTSPLY SIRONA (Nasdaq:XRAY) - Stock Analysis
This report provides a comprehensive stock analysis of DENTSPLY SIRONA (Nasdaq:XRAY), highlighting its valuation, future growth prospects, past performance, financial health, and dividend information. The company, which develops and markets dental equipment and healthcare consumable products, is currently trading at a significant discount to its estimated fair value, with analysts forecasting strong earnings growth. The article also details recent news, analyst commentary, and competitor comparisons.
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
DENTSPLY SIRONA (XRAY) is set to release its first-quarter 2026 earnings on May 5, with analysts forecasting revenues of $840.1 million and EPS of 28 cents. The company's performance is expected to be impacted by continued softness in the U.S. market, tariff-related pressures, and investments in its "Return-to-Growth" transformation plan. Despite some anticipated challenges, international markets, especially Europe, may offer resilience, while investors will be closely watching for signs of stabilization in the U.S. and progress on strategic initiatives.
Dentsply Sirona Releases FDA-Cleared Dental AI
Dentsply Sirona has launched Smart View – Detect, an FDA-cleared AI-enabled diagnostic aid designed to help dentists more efficiently detect periapical radiolucencies (PARLs) in CBCT scans. This technology increases detection sensitivity by approximately 46% without significantly increasing false positives, aiding clinicians in reviewing complex data and communicating findings to patients. Smart View – Detect supports confident evaluations, efficient work, and clearer patient communication for both new and existing compatible Dentsply Sirona CBCT systems.
In testing, dental scan AI lifted detection of a common tooth finding 46%
Dentsply Sirona (NASDAQ:XRAY) has launched Smart View - Detect, the first FDA-cleared AI-enabled diagnostic aid for detecting periapical radiolucencies (PARLs) in CBCT scans. An internal study showed an approximate 46% relative increase in tooth-level PARL detection sensitivity compared to unaided review. This tool, available May 12, 2026, through DS Core, aims to support clinicians in reviewing scans and communicating findings to patients more effectively.
Dentsply Sirona Launches Smart View - Detect, World’s First
Dentsply Sirona has launched Smart View - Detect, the world's first FDA-cleared AI-enabled diagnostic aid for detecting periapical radiolucencies (PARLs) in CBCT scans. This technology is designed to increase detection sensitivity by approximately 46% and improve patient communication by visually highlighting potential PARLs. Available through DS Core for both new and existing Dentsply Sirona CBCT systems, it will be released on May 12, 2026, in the United States and Europe.
Dentsply Sirona Launches Smart View - Detect, World’s First FDA-Cleared AI-enabled diagnostic aid for detecting teeth with Periapical Radiolucencies in CBCTs
Dentsply Sirona has launched Smart View - Detect, the world's first FDA-cleared and CE-approved AI-enabled diagnostic aid designed to help dentists identify teeth with periapical radiolucencies (PARLs) in CBCT scans. This tool, available through DS Core, increases PARL detection sensitivity by approximately 46% and aids in clearer patient communication without meaningfully increasing false positives. It is compatible with new and existing Dentsply Sirona CBCT systems and will be available starting May 12, 2026.
DENTSPLY SIRONA Expands Continence Care Reach With Surity Male Catheter
DENTSPLY SIRONA, through its subsidiary Wellspect HealthCare, has launched the Surity Male External Catheter in the U.S., expanding its non-invasive continence care portfolio. This move diversifies DENTSPLY SIRONA's offerings beyond its core dental business and aims to tap into a growing market for urinary incontinence solutions. Investors should monitor product adoption, reimbursement dynamics, and clinician acceptance to assess the impact on the company's risk and opportunity profile.
DENTSPLY SIRONA (XRAY): Among the Best Medical Stocks to Buy Under $30
DENTSPLY SIRONA Inc. (XRAY) is highlighted as one of the best medical stocks under $30, despite a recent price target cut by Evercore ISI from $15 to $13. Ariel Investments, which added XRAY to its portfolio, views the dental market favorably, citing steady growth, lower reimbursement risk, and higher out-of-pocket spending, believing Dentsply Sirona is well-positioned for long-term shareholder value through strategic resets. The company is the world's largest manufacturer of professional dental products and technologies.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Recommendation of "Hold" by Analysts
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has received a consensus "Hold" rating from fourteen analysts, with an average 12-month price target of $13.91. The company recently reported a slight miss on quarterly EPS ($0.27 vs. $0.28) but exceeded revenue expectations ($961M vs. $926.4M), while setting FY2026 EPS guidance of $1.40-$1.50. Insider transactions show recent purchases of approximately 70,000 shares, and institutional investors hold about 95.7% of the stock.
Cash per share of DENTSPLY SIRONA, Inc. – DUS:DY2
This article provides financial information for DENTSPLY SIRONA, Inc., specifically focusing on its "Cash per share" metric. It notes that market data is provided by ICE Data Services and reference data by FactSet, with SEC filings from Quartr. The information is available on TradingView under the Dusseldorf Stock Exchange listing DY2.
Vanguard reports 10.53M Dentsply Sirona shares (NASDAQ: XRAY)
Vanguard Capital Management has reported beneficial ownership of 10,529,427 shares of Dentsply Sirona (NASDAQ: XRAY), representing 5.27% of the common stock. This disclosure was made in a Schedule 13G filing on April 29, 2026. The filing indicates Vanguard has sole voting power over 1,529,870 shares and sole dispositive power over all 10,529,427 shares, signifying a passive investment stake.
[SCHEDULE 13G] DENTSPLY SIRONA Inc. Passive Investment Disclosure (>5%)
Vanguard Portfolio Management has filed a Schedule 13G for DENTSPLY SIRONA Inc. (XRAY), disclosing beneficial ownership of 10,724,505 shares, which represents 5.36% of the company's common stock as of March 31, 2026. The filing indicates Vanguard exercises sole voting power for 193,759 shares and sole dispositive power for all 10,724,505 shares. This disclosure, signed on April 29, 2026, by Ashley Grim, signifies a passive investment.
DENTSPLY SIRONA (XRAY) Expected to Announce Earnings on Tuesday
DENTSPLY SIRONA (NASDAQ:XRAY) is anticipated to release its Q1 2026 earnings before the market opens on Tuesday, May 5th, with analysts forecasting earnings of $0.29 per share and revenue of $843.3 million. The company's prior quarter results showed a slight miss on EPS but beat revenue expectations, with current shares trading around $11.71. Insider activity indicates recent share purchases, and institutional investors hold a significant portion of the stock.
94,400 Shares in DENTSPLY SIRONA Inc. $XRAY Bought by Skylands Capital LLC
Skylands Capital LLC recently acquired 94,400 shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the fourth quarter, valued at approximately $1.08 million. Other institutional investors also increased their holdings, pushing total institutional ownership to about 95.7%. Insider activity included purchases by Director James D. Forbes and Director Gregory T. Lucier, while analysts currently rate the stock as "Hold" with an average target price of $14.08.
Dentsply Sirona Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Dentsply Sirona Inc. (NASDAQ: XRAY) and reminds investors of the August 1, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Dentsply Sirona inflated its revenue and earnings through accounting manipulation of a distributor rebate program, misleading investors and resulting in artificially inflated stock prices. Investors who suffered losses exceeding $100,000 between June 9, 2021, and May 9, 2022, are encouraged to contact the firm.
Cwm LLC Lowers Stake in DENTSPLY SIRONA Inc. $XRAY
Cwm LLC significantly reduced its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 54.4% in the fourth quarter, selling 228,704 shares and ending the period with 191,766 shares valued at approximately $2.19 million. Despite this, other institutional investors increased their holdings, and company insiders recently bought shares. Analyst ratings are mixed, with a consensus "Hold" rating and a target price of $14.08, while Q4 revenue beat estimates but EPS narrowly missed.
